The Indian Network of Drug-Induced Liver Injury: Etiology, Clinical Features, Outcome and Prognostic Markers in 1288 Patients.
AED, Anti-epileptic drugs
ALF, Acute liver failure
ALT, Alanine aminotransferase
ART, Anti-retroviral drugs
AST, Aspartate aminotransferase
ATD, Anti- tuberculosis drugs
Anti-tuberculosis drugs
C.I, Confidence interval
CAM, Complementary and alternative medicine
Complimentary medicines
DILI, Drug-induced liver injury
DILIN, Drug induced liver injury network
HE, Hepatic encephalopathy
HIV, Human immunodeficiency virus
INR, International normalised ratio
Isoniazid
Jaundice
MELD, Model for end stage liver disease
Mortality
NSAID, Nonsteroidal anti-inflammatory drugs
OR, Odds ratio
Prognosis
Pyrazinamide
ROC, Receiver operating characteristic
RUCAM, Roussel uclaf causality assessment method
Rifampicin
TB, Tuberculosis.
TCM, Traditional chinese medicines.
Traditional medicines
ULN, Upper limit of normal
USA, United states of america
Journal
Journal of clinical and experimental hepatology
ISSN: 0973-6883
Titre abrégé: J Clin Exp Hepatol
Pays: India
ID NLM: 101574137
Informations de publication
Date de publication:
Historique:
received:
21
06
2020
accepted:
09
11
2020
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
ppublish
Résumé
Etiology of and outcomes following idiosyncratic drug-induced liver injury (DILI) vary geographically. We conducted a prospective study of DILI in India, from 2013 to 2018 and summarize the causes, clinical features, outcomes and predictors of mortality. We enrolled patients with DILI using international DILI expert working group criteria and Roussel Uclaf causality assessment method. Follow-up was up to 3 months from onset of DILI or until death. Multivariate logistics regression was carried out to determine predictors of non-survival. Among 1288 patients with idiosyncratic DILI, 51.4% were male, 68% developed jaundice, 68% required hospitalization and 8.2% had co-existing HIV infection. Concomitant features of skin reaction, ascites, and encephalopathy (HE) were seen in 19.5%, 16.4%, and 10% respectively. 32.4% had severe disease. Mean MELD score at presentation was 18.8 ± 8.8. Overall mortality was 12.3%; 65% in those with HE, 17.6% in patients who fulfilled Hy's law, and 16.6% in those that developed jaundice. Combination anti-TB drugs (ATD) 46.4%, complementary and alternative medicines (CAM) 13.9%, anti-epileptic drugs (AED) 8.1%, non-ATD antimicrobials 6.5%, anti-metabolites 3.8%, anti-retroviral drugs (ART)3.5%, NSAID2.6%, hormones 2.5%, and statins 1.4% were the top 9 causes. Univariate analysis identified, ascites, HE, serum albumin, bilirubin, creatinine, INR, MELD score (p < 0.001), transaminases (p < 0.04), and anti-TB drugs (p = 0.02) as predictors of non-survival. Only serum creatinine (p = 0.017), INR (p < 0.001), HE (p < 0.001), and ascites (p = 0.008), were significantly associated with mortality on multivariate analysis. ROC yielded a C-statistic of 0.811 for MELD and 0.892 for combination of serum creatinine, INR, ascites and HE. More than 50 different agents were associated with DILI. Mortality varied by drug class: 15% with ATD, 13.6% with CAM, 15.5% with AED, 5.8% with antibiotics. In India, ATD, CAM, AED, anti-metabolites and ART account for the majority of cases of DILI. The 3-month mortality was approximately 12%. Hy's law, presence of jaundice or MELD were predictors of mortality.
Sections du résumé
BACKGROUND
BACKGROUND
Etiology of and outcomes following idiosyncratic drug-induced liver injury (DILI) vary geographically. We conducted a prospective study of DILI in India, from 2013 to 2018 and summarize the causes, clinical features, outcomes and predictors of mortality.
METHODS
METHODS
We enrolled patients with DILI using international DILI expert working group criteria and Roussel Uclaf causality assessment method. Follow-up was up to 3 months from onset of DILI or until death. Multivariate logistics regression was carried out to determine predictors of non-survival.
RESULTS
RESULTS
Among 1288 patients with idiosyncratic DILI, 51.4% were male, 68% developed jaundice, 68% required hospitalization and 8.2% had co-existing HIV infection. Concomitant features of skin reaction, ascites, and encephalopathy (HE) were seen in 19.5%, 16.4%, and 10% respectively. 32.4% had severe disease. Mean MELD score at presentation was 18.8 ± 8.8. Overall mortality was 12.3%; 65% in those with HE, 17.6% in patients who fulfilled Hy's law, and 16.6% in those that developed jaundice. Combination anti-TB drugs (ATD) 46.4%, complementary and alternative medicines (CAM) 13.9%, anti-epileptic drugs (AED) 8.1%, non-ATD antimicrobials 6.5%, anti-metabolites 3.8%, anti-retroviral drugs (ART)3.5%, NSAID2.6%, hormones 2.5%, and statins 1.4% were the top 9 causes. Univariate analysis identified, ascites, HE, serum albumin, bilirubin, creatinine, INR, MELD score (p < 0.001), transaminases (p < 0.04), and anti-TB drugs (p = 0.02) as predictors of non-survival. Only serum creatinine (p = 0.017), INR (p < 0.001), HE (p < 0.001), and ascites (p = 0.008), were significantly associated with mortality on multivariate analysis. ROC yielded a C-statistic of 0.811 for MELD and 0.892 for combination of serum creatinine, INR, ascites and HE. More than 50 different agents were associated with DILI. Mortality varied by drug class: 15% with ATD, 13.6% with CAM, 15.5% with AED, 5.8% with antibiotics.
CONCLUSION
CONCLUSIONS
In India, ATD, CAM, AED, anti-metabolites and ART account for the majority of cases of DILI. The 3-month mortality was approximately 12%. Hy's law, presence of jaundice or MELD were predictors of mortality.
Identifiants
pubmed: 33994711
doi: 10.1016/j.jceh.2020.11.002
pii: S0973-6883(20)30175-4
pmc: PMC8103312
doi:
Types de publication
Journal Article
Langues
eng
Pagination
288-298Informations de copyright
© 2020 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.
Références
J Gastroenterol Hepatol. 2013 Jan;28(1):161-7
pubmed: 23020522
Hepatology. 2010 May;51(5):1665-74
pubmed: 20196116
Liver Int. 2020 Apr;40(4):825-829
pubmed: 31991029
Am J Gastroenterol. 2012 Sep;107(9):1380-7
pubmed: 22733303
Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):235-9
pubmed: 16552792
Gastroenterology. 2005 Aug;129(2):512-21
pubmed: 16083708
Ann Intern Med. 2002 Dec 17;137(12):947-54
pubmed: 12484709
Clin Pharmacol Ther. 2011 Jun;89(6):806-15
pubmed: 21544079
Lancet. 1993 Jul 31;342(8866):273-5
pubmed: 8101303
Indian J Gastroenterol. 2018 Jan;37(1):9-17
pubmed: 29476406
Am J Gastroenterol. 2019 Jun;114(6):929-937
pubmed: 31021832
Gastroenterology. 2019 Jun;156(8):2230-2241.e11
pubmed: 30742832
Semin Liver Dis. 2014 May;34(2):145-61
pubmed: 24879980
Am J Gastroenterol. 2010 Nov;105(11):2396-404
pubmed: 20648003
Hum Exp Toxicol. 2014 Sep;33(9):928-39
pubmed: 24299907
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Hepatology. 2002 Aug;36(2):451-5
pubmed: 12143055
J Clin Epidemiol. 1993 Nov;46(11):1323-30
pubmed: 8229110
Dig Dis Sci. 2016 Aug;61(8):2406-2416
pubmed: 27003146
Gastroenterology. 2013 Jun;144(7):1419-25, 1425.e1-3; quiz e19-20
pubmed: 23419359
JAMA. 2002 Jan 16;287(3):337-44
pubmed: 11790213
Gastroenterology. 2015 Jun;148(7):1340-52.e7
pubmed: 25754159
Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):241-3
pubmed: 16552790
Liver Int. 2018 Jul;38(7):1322-1329
pubmed: 29222960
Hepatology. 2005 Aug;42(2):481-9
pubmed: 16025496
Clin Gastroenterol Hepatol. 2018 Jun;16(6):936-946
pubmed: 29199145
BMC Med. 2018 Mar 28;16(1):46
pubmed: 29592805
Ann Hepatol. 2017 May - Jun 2017;16(3):442-450
pubmed: 28425415